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Abstract
Background: The inducible Cre-lox system is a valuable tool to study gene function in a spatial and time restricted fashion
in mouse models. This strategy relies on the limited background activity of the modified Cre recombinase (CreER) in the
absence of its inducer, the competitive estrogen receptor ligand, tamoxifen. The RIP-CreER mouse (Tg (Ins2-cre/Esr1) 1Dam)
is among the few available b-cell specific CreER mouse lines and thus it has been often used to manipulate gene expression
in the insulin-producing cells of the endocrine pancreas.
Principal Findings: Here, we report the detection of tamoxifen-independent Cre activity as early as 2 months of age in RIP-
CreER mice crossed with three distinct reporter strains.
Significance: Evidence of Cre-mediated recombination of floxed alleles even in the absence of tamoxifen administration
should warrant cautious use of this mouse for the study of pancreatic b-cells.
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Introduction
The inducible Cre-lox system has become an important tool for
the conditional deletion or expression of genes of interest within a
given cell type [1]. For this reason it has been widely used for
lineage tracing of cells during embryonic development and in adult
mice [2]. These studies typically require two mouse lines: a mouse
in which the inducible Cre recombinase is driven by a tissue/cell-
specific promoter and the target or reporter mouse, in which the
desired gene contains two loxP sites for Cre-mediated recombi-
nation [1]. Specifically, the bacteriophage P1 Cre recombinase
catalyzes site-specific recombination between two loxP sites and
efficiently excises DNA flanked by two loxP sites in the same
orientation [3]. Cre recombinase was made inducible by fusing it
with the ligand-binding domain (LBD) of the estrogen receptor
(ER) [4]. In the absence of its ligand, CreER is inactive as it is
confined to the cytoplasm, via binding to heat shock protein-90.
Upon estrogen binding, CreER moves into the nucleus where it
engages its DNA targets. To avoid the unwanted effects of
endogenous estrogen binding, the estrogen LBD has been further
mutated, leading to the generation of several CreER recombinases
that are sensitive to the synthetic ligand 4-hydroxytamoxifen (4-
OHT) but not to estradiol [5]. For example, the CreER
T
recombinase contains the human ER-LBD with a G521R
mutation [5], while CreER
TM contains the mouse ER-LBD with
a G525R mutation [6]. Different versions of CreER are being
developed to decrease their nuclear translocation in the absence of
the inducer, while increasing their sensitivity to tamoxifen and
their recombination efficiency. More recent and useful CreER
variants include MerCreMer, a double fusion of Cre with two
ER
TM domains [7], and CreER
T2 (G400V/M543A/L544A triple
mutation of human ER-LBD) [8]. The complete absence of
nuclear CreER without tamoxifen induction is crucial for
conditional systems, because even the effects of a minor leakiness
will accumulate over time due to the irreversibility of every
recombination event. Cell adaptation to the altered gene
expression pattern induced by the CreER recombinase, even in
the absence of tamoxifen, can complicate further the analysis of
gene function or cell lineage tracing studies. Therefore, the
availability of mouse strains with tightly controlled CreER activity
is highly desirable.
The RIP-CreER mouse (Tg (Ins2-cre/Esr1) 1Dam) was originally
reported in 2004 and employed to investigate the origin of newly
generated insulin-producing cells (b-cells) in adult mice and
following partial pancreatectomy [9]. In this line, the use of the
rat insulin promoter 2 to drive the expression of CreER restricts
the expression of the recombinase to pancreatic b-cells. To further
study the biology of pancreatic b-cells we crossed this RIP-CreER
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(R26-Stop-HA3-ICA512-CCF) for the conditional overexpression of
the cleaved cytosolic fragment of ICA512 (ICA512-CCF) [10], a
Rosa26-lacZ reporter mouse [11] and a PTBP1
loxP/loxP line for the
conditional knockout of PTBP1 [12]. Our data indicate that in all
three cases recombination of the Cre-target genes was triggered
very early on, in the absence of tamoxifen treatment.
Results
Tamoxifen-independent recombination in the Rosa26
locus of RIP-CreER mice
To study the function of ICA512-CCF in vivo, we generated the
R26-Stop-HA3-ICA512-CCF knock-in mouse, in which three-HA-
tagged ICA512-CCF preceded by a floxed Stop cassette was
introduced into the Rosa26 locus. The R26-Stop-HA3-ICA512-CCF
mouse was then crossed with the RIP-CreER mouse [9] (Fig. 1A).
In principle, in the progeny containing both transgenes, the b-cell
restricted expression of HA3-ICA512-CCF should have been
detectable only upon tamoxifen-induced removal of the floxed
Stop cassette (Fig. 1A). Western blotting with an anti-HA
antibody, however, revealed the expression of HA3-ICA512-
CCF in islets isolated from 3-month-old RIP-CreER, R26-Stop-
HA3-ICA512-CCF mice regardless of tamoxifen treatment
(Fig. 1B). In the control, HA3-ICA512-CCF was not detected
in the extract of islets from R26-Stop-HA3-ICA512-CCF single
transgenic littermates (Fig. 1B). Cryosections of pancreatic tissue
from 3-and 4-month-old mice were examined by immunofluores-
cence microscopy using anti-HA and anti-insulin antibodies.
Immunoreactivity for HA was readily detectable in insulin-positive
cells, i.e. in b-cells, of tamoxifen-treated RIP-CreER, R26-Stop-
HA3-ICA512-CCF mice (Fig. 1C-F). The specificity of this
labeling was confirmed by the absence of immunoreactivity for
HA in pancreatic sections of tamoxifen-treated R26-Stop-HA3-
ICA512-CCF mice (Fig. 1G-J). However, a positive reactivity for
HA was also present in pancreatic sections of RIP-CreER, R26-
Stop-HA3-ICA512-CCF mice that had not been treated with
tamoxifen (Fig. 1K-N). Quantification of 15 islets from 3 mice
in each genotype group revealed that at 4-month age,
70%612.8% (mean 6 SD) of the insulin positive cells were also
positive for HA3-ICA512-CCF in non-treated RIP-CreER, R26-
Stop-HA3-ICA512-CCF mice compared to 87.9%67.4% in
tamoxifen-treated RIP-CreER, R26-Stop-HA3-ICA512-CCF mice
(Fig. 1O). Taken together, these data indicate that in these mice
nuclear translocation of CreER occurred even in the absence of
tamoxifen.
To evaluate whether the tamoxifen-independent expression of
HA3-ICA512-CCF was a specific limit of the RIP-CreER, R26-
Stop-HA3-ICA512-CCF mouse, we then bred RIP-CreER mice to
Rosa26-lacZ mice, in which the b-galactosidase gene (lacZ) preceded
by a floxed Stop cassette is inserted in the Rosa26 locus [11]. In
10-week-old, tamoxifen-untreated RIP-CreER, Rosa26-lacZ mice
42.9%613.1% of the islet area was lacZ positive (Fig. 2C, 2D)
compared to 80.2%612.9% upon tamoxifen-treatment (Fig. 2A,
2D). Conversely, no lacZ-positive islets were found in tamoxifen-
treated Rosa26-lacZ littermates (Fig. 2B, 2D). These findings
corroborate the conclusion that the RIP-CreER mouse displays a
tamoxifen-independent recombinase activity, at least toward
transgenes introduced in the Rosa26 locus.
Tamoxifen-independent recombination outside of the
Rosa26 locus in the RIP-CreER mouse
To evaluate whether the constitutive Cre activity detected in
RIP-CreER mice is limited to the Rosa26 locus, we analyzed RIP-
CreER, PTBP1
loxP/loxP mice. PTBP1 (polypyrimidine tract-binding
protein 1) [12] is an RNA-binding protein that, in insulinoma
INS-1 cells, enhances the stability and translation of mRNAs
encoding insulin granule proteins [13]. The insertion of two loxP
sites flanking exons 3 to 7 of PTBP1 allows the deletion of this gene
(Suckale et al., in preparation). Pancreatic sections of 8-week-old
RIP-CreER, PTBP1
loxP/loxP mice treated or untreated with tamox-
ifen were examined by immunocytochemistry for the expression of
insulin and PTBP1. In tamoxifen-treated RIP-CreER, PTBP1
loxP/
loxP mice 60 ˜1%612.6% of the insulin positive cells were negative
for PTBP1 compared to 61.9%68.4% in the case of tamoxifen
untreated mice (Fig. 3A-D, 3I-M). In contrast, virtually all b-cells
of tamoxifen treated PTBP1
loxP/loxP mice were PTBP1 positive
(Fig. 3E-H, 3M). Thus, Cre-induced knockout of PTBP1
occurred in most b-cells regardless of tamoxifen-treatment.
Subtle Tamoxifen-independent recombination in the
Rosa26 locus of Pdx1-CreER mice
Next, we evaluated the tamoxifen-independent recombination
of Pdx1-CreER mouse [14]. Upon crossing this mouse with the
Rosa26-lacZ mouse employed previously, we detected tamoxifen-
independent X-gal staining only in few b-cells of 2-, 4- and 6-
month-old mice (Fig. 4A-D and Data not shown). Morpho-
metric analysis, in particular, showed that in 4-month-old
tamoxifen-untreated Pdx1-CreER, Rosa26-lacZ mice only
4.6%63.4% of the islet area was lacZ positive compared to
83%68.3% upon tamoxifen treatement (Fig. 4D).
Discussion
In the original study the RIP-CreER was bred with a Z/AP
reporter strain [9]. The authors wrote that: ‘‘by 10 months of age,
double transgenic mice that did not receive tamoxifen had
occasionally one to five HPAP
+ cells per islet, reflecting the
cumulative lifetime leakage of the system.’’ [9]. In our case the
leakiness of the system was clearly stronger. Its tamoxifen-
independent recombinase activity was detected in 3 different
reporter/target mice, 2 loci and was already pronounced at 2
months of age. There are at least two possible explanations for
these discrepancies. One possibility is that after many generations
of backcrossing to the C57BL/6 background, the expression of the
randomly integrated RIP-CreER transgene is enhanced, thus
increasing the probability of its nuclear entry, even in tamoxifen-
untreated cells. Another more likely possibility is that the Z/AP
cassette in the Z/AP reporter mouse strain is less prone to
recombination, i.e. it is inserted in an area of the chromatin less
amenable to recombination. Easy access of the CreER to the
target locus may result in both high recombination efficiency and
leakiness of the system as seen in the 3 lines described here. On the
other hand, recombination of a less accessible, heterochromatic
locus could be less efficient, but also less leaky, as in the case of the
Z/AP mouse.
One way to mitigate such problems is the use of the Pdx1-CreER
mouse, which was also generated in the Melton lab [14]. Upon its
crossing with the Rosa26-lacZ mouse, we found that in this mouse
tamoxifen-independent recombination is a relative rare event. As
both Pdx1-CreER and RIP-CreER mice were generated using the
CreER
TM variant, the tighter phenotype of the former is
conceivably due to the lower activity of the Pdx-1 promoter
relative to the RIP promoter, resulting in lower expression of
CreER
TM. Buelow and Scharenberg have recently shown in cell
lines that the ligand-independent activity of inducible Cre
correlates with its level of expression [15]. Hence, CreER
transgenic mice should be carefully evaluated regarding the
RIP-CreER Leaky Recombination
PLoS ONE | www.plosone.org 2 October 2010 | Volume 5 | Issue 10 | e13533Figure 1. Tamoxifen-independent expression of HA3-ICA512-CCF in b-cells of RIP-CreER, R26-Stop-HA3-ICA512-CCF mice. A. Strategy for
the generation of the inducible R26-Stop-HA3-ICA512-CCF knock-in mouse line. B. Western blotting of pancreatic islet extracts from 3-month-old
tamoxifen-treated or untreated RIP-CreER, R26-Stop-HA3-ICA512-CCF mice or tamoxifen-treated R26-Stop-HA3-ICA512-CCF mice with anti-HA and anti-
c-tubulin antibodies (similar results were obtained from 3 independent experiments). C-N. Confocal microscopy images of pancreatic cryosections
from 4-month-old tamoxifen-treated RIP-CreER, R26-Stop-HA3-ICA512-CCF (C-F) and R26-Stop-HA3-ICA512-CCF (G-J) and untreated RIP-CreER, R26-Stop-
HA3-ICA512-CCF (K-N) mice stained with DAPI (C, G and K), as well as with anti-insulin (D, H and L) and anti-HA antibodies (E, I and M). Triple stainings
RIP-CreER Leaky Recombination
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study of b-cells could also benefit from the development of
additional driver mice in which a single copy of Cre fused to one
or even two ER
T2 domains is inserted downstream of a b-cell
specific promoter, such as insulin, using BAC-based recombina-
tion technologies.
In conclusion, we observed tamoxifen-independent recombina-
tion in the RIP-CreER mouse already in early adult age.
Investigators working in the field of islet biology should be aware
of this potential hurdle when planning the employment of this
mouse for their studies.
Materials and Methods
Ethics statement
All animal experiments were conducted in a licensed animal
facility in accordance with the German Animal Welfare Act, following
the guidelines of the European Convention for the Protection of Vertebrate
Animals Used for Experimental and Other Scientific Purposes and approved
by the regional council.
Generation of the R26-Stop-HA3-ICA512-CCF mouse
Primers NheI-SA-F-46 (59- attatagctagcgtgacctgcacgtctagggcg-
cagtagtccaggg -39) and NheI-SA-MCS-R-117 (59-Tataatgctag-
cacgcgtatataattcccgggttcgaatctagaatataattccgcggac tggaaagaccgc-
gaagagtttgtcctcaaccgcgagctgtggaaaaaaaagggacag -39) were used
to amplify SA-MCS (Splice Acceptor and Multiple Cloning Site)
fragment using the plasmid pMB80 (R26-CreER, from Addgene)
as template. SA-MCS (digested with NheI) was cloned into the
pROSA26-1 vector (plasmid pMB80 digested with XbaI) to obtain
the pROSA26-SA-MCS construct. XhoI and ClaI were used to
remove PGK-DTA from pROSA26-SA-MCS and obtain
pROSA26-SA-MCS-dPGK-DTA. Primers SacII-r-loxP-F (attat-
accgcggataacttcgtatagcatacattatacgaagttattaggtccctcgacctgcaggaattc)
and NheI-r-loxP-R (ttattagctagctataacttcgtataatgtatgctatacgaagtta-
tattaagggttccggatcagcttgatgg) were used to amplify the loxP-Stop-
Figure 2. b-galactosidase gene (lacZ) expression in RIP-CreER, Rosa26-lacZ mice. A-C. LacZ staining of the pancreatic tissue from 10-week-old
tamoxifen-treated RIP-CreER, Rosa26-lacZ mice (A), and Rosa26-lacZ (B) and untreated RIP-CreER, Rosa26-lacZ (C) mice. D. Quantification and statistical
analysis of the lacZ-positive area relative to the total islet area in tamoxifen-treated or untreated RIP-CreER, Rosa26-lacZ mice, and tamoxifen-treated
Rosa26-lacZ mice. Dots represent individual islets from 3 mice in each genotype group. The p value of a t-test between groups is shown.
doi:10.1371/journal.pone.0013533.g002
(merge) are shown in F, J and N. Scale bars in F, J and N equal 10 mm. O. Quantification and statistical analysis of HA3-ICA512-CCF-positive cells
relative to total insulin-positive cells in tamoxifen-treated or untreated RIP-CreER, R26-Stop-HA3-ICA512-CCF mice, and tamoxifen-treated R26-Stop-
HA3-ICA512-CCF mice. Dots represent individual islets from 3 mice in each genotype group. The p value of a t-test between groups is shown.
doi:10.1371/journal.pone.0013533.g001
RIP-CreER Leaky Recombination
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Stop-loxP (digested with SacII and NheI) fragment was then ligated
with pROSA26-SA-MCS-d-PGK-DTA (digested with SacII and
XbaI) to obtain pROSA26-Stop. HA3-ICA512-CCF [16] (digested
with EcoRI and MluI) was ligated with HSV-TK-39UTR (digested
with MfeI and MluI), which was amplified with primers MfeI-HSV-
TK-39UTR-F and MluI-HSV-TK-39UTR-R from pEGFPN1.
HA3-ICA512-CCF-HSV-TK-39UTR (digested with AgeI and
MluI) was then cloned into pROSA26-Stop (digested with XmaI
and MluI) to obtain the final construct pR26-Stop-HA3-ICA512-
CCF (GenBank accession number HM588138). All the constructs
were confirmed to be correct by sequencing. pR26-Stop-HA3-
ICA512-CCF was digested by PacI and KpnI and then electropo-
rated into R1 embryonic stem (ES) cells (129 genetic background),
which were then selected for resistance to G418. The targeted ES
cells in which the floxed Stop cassette and HA3-ICA512-CCF
Figure 3. Tamoxifen-independent knockout of PTBP1 in adult b-cells of RIP-CreER, PTBP1
loxP/loxP mice. A-L. Confocal microscopy images of
pancreatic cryosections from 8-week-old tamoxifen-treated RIP-CreER, PTBP1
loxP/loxP (A-D) and PTBP1
loxP/loxP (E-H) and untreated RIP-CreER, PTBP1
loxP/loxP
(I-L) mice stained with DAPI (A, E and I), as well as with anti-PTBP1 (B, F and J) and anti-insulin antibodies (C, G and K). Triple stainings (merge) are shown
inD,HandL.ScalebarsinD,HandLequal20 mm.M.QuantificationandstatisticalanalysisofPTBP1-positivecellsrelativetototalinsulin-positivecellsin
tamoxifen-treated and untreated RIP-CreER, PTBP1
loxP/loxP mice, and tamoxifen-treated PTBP1
loxP/loxP mice. Dots represent individual islets from 4 mice in
each genotype group. The p value of a t-test between groups is shown.
doi:10.1371/journal.pone.0013533.g003
RIP-CreER Leaky Recombination
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Rosa26 locus were identified by Southern blots with 59-arm, 39-arm
and internal probes. The ES cells were injected into eight-cell mouse
embryos togeneratethe R26-Stop-HA3-ICA512-CCF mousefounder.
Primers pRosa26-1-757-77 (59-gtttccgacttgagttgcctc-39) and unrec-R
(59- ccacttgtgtagcgccaagtg-39) were used for PCR-genotyping of
mice. The mouse R26-Stop-HA3-ICA512-CCF line was kept in the
129X1 SvJ genetic background.
Generation of conditional PTBP1 knockout mouse
In the PTBP1
loxP/lopP mouse, two loxP sites flank exons 3 to 7 of
PTBP1. The detailed information regarding this mouse generation
is described elsewhere (Suckale et al., in preparation). The
GenBank accession number of the related construct is HM588137.
Tamoxifen treatment
3–5 mg tamoxifen (Sigma, Cat# T-5648) were fed to the mice
by gavage, every other day and 3 times in total.
Immunohistochemistry
Cryosections were re-hydrated in PBS, permeabilized with
0.3% Triton X-100 in PBS for 15 min, and incubated for 1 hour
in blocking buffer (goat serum dilution buffer). Sections were
incubated with primary antibodies in the blocking buffer overnight
at 4uC, washed with PBS, then further incubated with the
appropriate fluorochrome-conjugated secondary antibodies raised
in goat for 1 hour. Sections were finally rinsed with water and
mounted using Moviol solution. Primary antibodies included a
mouse anti-HA antibody (Roche), a guinea pig anti-insulin
antibody (Gene Tex), and a mouse anti-PTBP1 antibody (Zymed).
Confocal images were acquired on a Zeiss LSM 510 microscope.
Total number of insulin positive cells as well as insulin/HA3-
ICA512-CCF double positive cells or insulin positive/PTBP1
negative cells were counted manually from images processed with
the Fiji software [17]. The percentage and the p value of a t-test
between groups were calculated with Microsoft Excel.
Staining for b-galactosidase activity
Mouse pancreatic cryosections were fixed with 0.2% glutaral-
dehyde buffer (for 50 ml, 0.5 ml 0.5 M EGTA, pH 7.3; 5.0 ml
1 M MgCl2; 44.1 ml PBS; 0.4 ml 25% glutaraldehyde), and then
washed 3 times for 15 min in washing buffer (for 500 ml, 1.0 ml
1 M MgCl2; 5.0 ml 1% Sodium deoxycholate (NaDOC); 5.0 ml
2% Nonidet-P40; 489 ml PBS). The sections were further
Figure 4. b-galactosidase gene (lacZ) expression in Pdx1-CreER, Rosa26-lacZ mice. A-C. LacZ staining of the pancreatic tissue from 4-month-
old tamoxifen-treated Pdx1-CreER, Rosa26-lacZ mice (A), and Rosa26-lacZ (B) and untreated Pdx1-CreER, Rosa26-lacZ (C) mice. D. Quantification and
statistical analysis of the lacZ-positive area relative to the total islet area in tamoxifen-treated or untreated Pdx1-CreER, Rosa26-lacZ mice, and
tamoxifen-treated Rosa26-lacZ mice. Dots represent individual islets from 3 mice in each genotype group. The p value of a t-test between groups is
shown.
doi:10.1371/journal.pone.0013533.g004
RIP-CreER Leaky Recombination
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(5-bromo-4-chloro-3-indoxy-b-D-galactopyranoside)); 0.21 g K-
ferrOcyanide; 0.16 g K-ferrIcyanide in washing buffer) in a dark
chamber at 30uC overnight. The sections were counterstained
with haematoxylin, dehydrated through ethanol series and
mounted with Depex mounting medium.
Quantification of lacZ positive islet area in the islet
Images of sections stained for lacZ were taken with a Zeiss
Observer Z1 using a 40X objective. The images were then
analyzed with Adobe Photoshop and Fiji to measure the lacZ
positive islet area relative to the total islet area.
Islet isolation and western blot
Pancreatic islets were isolated as previous described [18]. After
24-hour culture, islets were harvested at 4uC in cell lysis buffer to
obtain total extracts. 10 mg protein was separated by 10% SDS-
PAGE and immunoblotted with a rabbit anti-HA antibody
(Abcam) and a mouse anti-c-tubulin antibody. The blot was
developed using the Supersignal West Pico or Femto kits (Pierce)
and Chemiluminescence was detected with a LAS 3000 Bioima-
ging System (Fuji, Tokyo, Japan).
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